ChemLifeIntel/Companies/Graviti Pharmaceuticals Private Limited

Graviti Pharmaceuticals Private Limited

HIGH RISKHQ: — · Private · Founded —

LISTINGPrivateFOUNDED0

FOCUS THERAPY AREAS

Manufacturer

COMPANY INTELLIGENCE SNAPSHOTlive

Manufacturing Sites

Intelligence Briefs

Active Regulatory Actions

—

HQ Country

NO ACTIVE REGULATORY ACTIONSClean compliance footprint across 0 monitored sites · HQ

View regulatory detail

INTELLIGENCE

Showing 2 of 2 briefs on Graviti Pharmaceuticals Private Limited

REGULATORY INTELLIGENCE·Recall

Graviti Pharmaceuticals Faces Second Class II Recall for Furosemide Due to Foreign Substance Contamination, Impacting Rising Pharma Supply

Graviti Pharmaceuticals Private Limited has initiated a Class II recall for Furosemide Tablets, USP 40 mg, due to a foreign substance, affecting 4,212 bottles distributed by Rising Pharma Holdings, Inc. This marks Graviti's second Class II recall in recent months, signaling escalating quality control deficiencies and significant supply chain risks for partners sourcing from their Hyderabad, India facility.

90-Day Activity

Graviti Pharmaceuticals Private LimitedFurosemide

RMRohan Mehta· Senior Supply Chain Intelligence Analyst

2026-01-28▲ Trending signal

REGULATORY INTELLIGENCE·Recall

Graviti Pharmaceuticals Initiates Class II Recall for Bupropion Hydrochloride ER 300mg Due to Failed Specifications

Graviti Pharmaceuticals Private Limited has initiated a Class II recall for 46,512 bottles of Bupropion Hydrochloride Extended-Release Tablets USP (XL), 300 mg, due to failed tablet specifications. This impacts supply chains relying on the Hyderabad, India facility and its distributor, Rising Pharma Holdings, Inc. Procurement and regulatory teams must assess immediate supply risks and evaluate alternative generic Bupropion sources to mitigate disruption and ensure patient access.

90-Day Activity

Graviti Pharmaceuticals Private LimitedMemantine Hydrochloride

PSPriya Subramaniam· Intelligence Analyst

2025-10-29